Relationships between PET and blood plasma biomarkers in corticobasal syndrome
Alzheimer's & Dementia · 2024
DOI: 10.1002/alz.13914 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Neha Atulkumar Singh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Biomarkers, tau Proteins, Amyloid beta-Peptides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDCD NIH HHS, NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
INTRODUCTION Corticobasal syndrome (CBS) can result from underlying Alzheimer's disease (AD) pathologies. Little is known about the utility of blood plasma metrics to predict positron emission tomography (PET) biomarker‐confirmed AD in CBS. METHODS A cohort of eighteen CBS patients (8 amyloid beta [Aβ]+; 10 Aβ−) and 8 cognitively unimpaired (CU) individuals underwent PET imaging and plasma analysis. Plasma concentrations were compared using a Kruskal–Wallis test. Spearman correlations assessed relationships between plasma concentrations and PET uptake. RESULTS CBS Aβ+ group showed a reduced Aβ42/40 ratio, with elevated phosphorylated tau (p‐tau)181, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) concentrations, while CBS Aβ− group only showed elevated NfL concentration compared to CU. Both p‐tau181 and GFAP were able to differentiate CBS Aβ− from CBS Aβ+ and showed positive associations with Aβ and tau PET uptake. DISCUSSION This study supports use of plasma p‐tau181 and GFAP to detect AD in CBS. NfL shows potential as a non‐specific disease biomarker of CBS regardless of underlying pathology. Highlights Plasma phosphorylated tau (p‐tau)181 and glial fibrillary acidic protein (GFAP) concentrations differentiate corticobasal syndrome (CBS) amyloid beta (Aβ)− from CBS Aβ+. Plasma neurofilament light concentrations are elevated in CBS Aβ− and Aβ+ compared to controls. Plasma p‐tau181 and GFAP concentrations were associated with Aβ and tau positron emission tomography (PET) uptake. Aβ42/40 ratio showed a negative correlation with Aβ PET uptake.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
- Department of Psychiatry & Psychology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Epidemiology and Prevention, Wake Forest University, Winston-Salem, North Carolina, USA.
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Förderung
- NIDCD NIH HHS
- NIH HHS
- NIA NIH HHS
- NINDS NIH HHS
- National Institutes of Health
Zitieren
APA
Singh, N. A., Alnobani, A., Graff-Radford, J., Machulda, M. M., Mielke, M. M., Schwarz, C. G., Senjem, M. L., Jack, C. R., Lowe, V. J., Kanekiyo, T., Josephs, K. A., & Whitwell, J. L. (2024). Relationships between PET and blood plasma biomarkers in corticobasal syndrome. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13914
Vancouver
Singh NA, Alnobani A, Graff-Radford J, Machulda MM, Mielke MM, Schwarz CG, et al. Relationships between PET and blood plasma biomarkers in corticobasal syndrome. Alzheimer's & Dementia. 2024. doi:10.1002/alz.13914
BibTeX
@article{Singh2024,
author = {Singh, Neha Atulkumar and Alnobani, Alla and Graff-Radford, Jonathan and Machulda, Mary M and Mielke, Michelle M and Schwarz, Christopher G and Senjem, Matthew L and Jack, Clifford R and Lowe, Val J and Kanekiyo, Takahisa and Josephs, Keith A and Whitwell, Jennifer L},
title = {Relationships between PET and blood plasma biomarkers in corticobasal syndrome},
journal = {Alzheimer's & Dementia},
year = {2024},
doi = {10.1002/alz.13914}
}
EUVIMED